These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
208 related articles for article (PubMed ID: 38301886)
1. Serotonergic Psychedelics: A Comparative Review of Efficacy, Safety, Pharmacokinetics, and Binding Profile. Holze F; Singh N; Liechti ME; D'Souza DC Biol Psychiatry Cogn Neurosci Neuroimaging; 2024 May; 9(5):472-489. PubMed ID: 38301886 [TBL] [Abstract][Full Text] [Related]
2. Psychedelics for treatment resistant depression: are they game changers? Kalfas M; Taylor RH; Tsapekos D; Young AH Expert Opin Pharmacother; 2023; 24(18):2117-2132. PubMed ID: 37947195 [TBL] [Abstract][Full Text] [Related]
3. Drug-drug interactions involving classic psychedelics: A systematic review. Halman A; Kong G; Sarris J; Perkins D J Psychopharmacol; 2024 Jan; 38(1):3-18. PubMed ID: 37982394 [TBL] [Abstract][Full Text] [Related]
4. The changing outlook of psychedelic drugs: The importance of risk assessment and occupational exposure limits. Videira NB; Nair V; Paquet V; Calhoun D J Appl Toxicol; 2024 Feb; 44(2):216-234. PubMed ID: 37646119 [TBL] [Abstract][Full Text] [Related]
5. Among psychedelic-experienced users, only past use of psilocybin reliably predicts nature relatedness. Forstmann M; Kettner HS; Sagioglou C; Irvine A; Gandy S; Carhart-Harris RL; Luke D J Psychopharmacol; 2023 Jan; 37(1):93-106. PubMed ID: 36601974 [TBL] [Abstract][Full Text] [Related]
7. Spectral signatures of serotonergic psychedelics and glutamatergic dissociatives. Pallavicini C; Vilas MG; Villarreal M; Zamberlan F; Muthukumaraswamy S; Nutt D; Carhart-Harris R; Tagliazucchi E Neuroimage; 2019 Oct; 200():281-291. PubMed ID: 31247301 [TBL] [Abstract][Full Text] [Related]
8. Present and future of metabolic and metabolomics studies focused on classical psychedelics in humans. Madrid-Gambin F; Fabregat-Safont D; Gomez-Gomez A; Olesti E; Mason NL; Ramaekers JG; Pozo OJ Biomed Pharmacother; 2023 Dec; 169():115775. PubMed ID: 37944438 [TBL] [Abstract][Full Text] [Related]
9. Comparative acute effects of mescaline, lysergic acid diethylamide, and psilocybin in a randomized, double-blind, placebo-controlled cross-over study in healthy participants. Ley L; Holze F; Arikci D; Becker AM; Straumann I; Klaiber A; Coviello F; Dierbach S; Thomann J; Duthaler U; Luethi D; Varghese N; Eckert A; Liechti ME Neuropsychopharmacology; 2023 Oct; 48(11):1659-1667. PubMed ID: 37231080 [TBL] [Abstract][Full Text] [Related]
10. Pharmacological and biotransformation studies of 1-acyl-substituted derivatives of d-lysergic acid diethylamide (LSD). Halberstadt AL; Chatha M; Klein AK; McCorvy JD; Meyer MR; Wagmann L; Stratford A; Brandt SD Neuropharmacology; 2020 Aug; 172():107856. PubMed ID: 31756337 [TBL] [Abstract][Full Text] [Related]
11. Hallucinogenic/psychedelic 5HT2A receptor agonists as rapid antidepressant therapeutics: Evidence and mechanisms of action. Dos Santos RG; Hallak JE; Baker G; Dursun S J Psychopharmacol; 2021 Apr; 35(4):453-458. PubMed ID: 33740877 [TBL] [Abstract][Full Text] [Related]
12. Psychedelics: Alternative and Potential Therapeutic Options for Treating Mood and Anxiety Disorders. Lowe H; Toyang N; Steele B; Grant J; Ali A; Gordon L; Ngwa W Molecules; 2022 Apr; 27(8):. PubMed ID: 35458717 [TBL] [Abstract][Full Text] [Related]